# Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis

> **NCT06554847** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- Dermatitis, Atopic
- Eczema, Atopic

## Interventions

- **DRUG:** 611
- **DRUG:** Placebo
- **DRUG:** Topical corticosteroid

## Key facts

- **NCT ID:** NCT06554847
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-23
- **Primary completion:** 2025-10-12
- **Final completion:** 2026-08-16
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06554847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06554847, "Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06554847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*